Analyst Insights

Janney Capital Maintains Buy On Vertex Ahead Of 2Q:14 Earnings Results

In a research report published today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX) with a $110 price …

Janney Capital Maintains Neutral On PDL Biopharma; $8 PT

In a research note released today, Janney Capital analyst Kimberly Lee maintained a Neutral rating on PDL Biopharma (PDLI) with a $8 price target, ahead of the upcoming …

NPS Pharmaceuticals: All Eyes Remain On Gattex Launch And Natpara Adcom Meeting, Says Janney

In a research note released this morning, Janney Capital analyst Kimberly Lee maintained a Buy rating on NPS Pharmaceuticals, Inc (NPSP) with a …

Medivation Remains One Of Our Top Ideas For 2014, Says Janney

In a research report issued today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Medivation Inc. (MDVN) with a $110 price target, which …

Janney Capital Maintains Buy On BioMarin Ahead Of 2Q:14 Earnings

In a research note released today, Janney Capital analyst Kimberly Lee maintained a Buy rating on BioMarin Pharmaceutical (BMRN) and a $65 price target, which represents …

Janney Capital Maintains Neutral On Alexion Despite A Positive Outlook For 2Q14 Results

In a research note published today, Janney Capital analyst Kimberly Lee maintained a Neutral rating on Alexion Pharmaceuticals (ALXN) with a $162 price …

Janney Capital Maintains Buy On Aegerion Ahead Of 2Q14 Earnings Report

In a research report released today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Aegerion Pharmaceuticals (AEGR) with a $90 price target, which …

Cypress: We Remain On The Sidelines Until Any Future Growth Drivers Can Be Addressed, Says Feltl

In a research report released today, Feltl and Company analyst Jeffrey Schreiner reiterated a Hold rating on Cypress Semiconductor (CY) with a $10 price …

Imax: Stock Is Likely To Strengthen As Focus Turns To 2015, Says Canaccord

In a research note released today, Canaccord Genuity analyst Aravinda Galappatthige reaffirmed a Buy rating on Imax Corporation (IMAX) with a price target of $34.50.

We Sensed Growing Momentum In The Field For F5, Says William Blair

In a research note released this morning, William Blair analyst Jason Ader reiterated an Outperform rating on F5 Networks (FFIV) ahead of the upcoming third-quarter results. …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts